Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

Expert opinion on investigational drugs - 1 Dec 2012

Tibes Raoul, Bogenberger James M, Geyer Holly L, Mesa Ruben A

Abstract excerpt

INTRODUCTION: Dysregulation of JAK-STAT signaling is a pathogenetic hallmark of myeloproliferative neoplasms (MPNs) arising from several distinct molecular aberrations, including mutations in JAK2, the thrombopoietin receptor (MPL), mutations in negative regulators of JAK-STAT signaling, such as lymphocyte-specific adapter protein (SH2B3), and epigenetic dysregulation as seen with Suppressor of Cytokine Signaling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bone Marrow Neoplasms
Share to MPL gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Share to STAT Transcription Factors

Source

Identifiers

PMID: 22991927
DOI: 10.1517/13543784.2012.721352

Genes

JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.PMID 22991927Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.Semantic proximity Read ↗

Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 in Myeloproliferative Neoplasms: Still a ProtagonistSemantic proximity Read ↗

The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Semantic proximity Read ↗

Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disordersSemantic proximity Read ↗

Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.